Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting.
about
Barriers in the implementation of isoniazid preventive therapy for people living with HIV in Northern Ethiopia: a mixed quantitative and qualitative study.Effect of secondary preventive therapy on recurrence of tuberculosis in HIV-infected individuals: a systematic review.Isoniazid-resistant tuberculosis: a cause for concern?An evaluation of factors associated with taking and responding positive to the tuberculin skin test in individuals with HIV/AIDS.Intensive case finding and isoniazid preventative therapy in HIV infected individuals in Africa: economic model and value of information analysisLatent and subclinical tuberculosis in HIV infected patients: a cross-sectional study.Efficacy of a six-month versus a 36-month regimen for prevention of tuberculosis in HIV-infected persons in India: a randomized clinical trialDiagnosing latent tuberculosis in high-risk individuals: rising to the challenge in high-burden areas.Debunking the myths perpetuating low implementation of isoniazid preventive therapy amongst human immunodeficiency virus-infected persons.Implementation of Tuberculosis Intensive Case Finding, Isoniazid Preventive Therapy, and Infection Control ("Three I's") and HIV-Tuberculosis Service Integration in Lower Income CountriesTreatment of latent tuberculosis infection in HIV: shorter or longer?Risk of Disease After Isoniazid Preventive Therapy for Mycobacterium tuberculosis Exposure in Young HIV-uninfected Children.Implementation and evaluation of an isoniazid preventive therapy pilot program among HIV-infected patients in Vietnam, 2008-2010Community-wide isoniazid preventive therapy drives drug-resistant tuberculosis: a model-based analysis.Performance of symptom-based tuberculosis screening among people living with HIV: not as great as hopedTuberculosis screening in high human immunodeficiency virus prevalence settings: turning promise into reality.Tuberculosis and HIV co-infection: screening and treatment strategies.Rifampicin resistance after treatment for latent tuberculous infection: a systematic review and meta-analysis."It's about my life": facilitators of and barriers to isoniazid preventive therapy completion among people living with HIV in rural South Africa.An observational study on the incidence of tuberculosis among a cohort of HIV infected adults in a setting with low prevalence of tuberculosis.Increase in anti-tuberculosis drug resistance in Botswana: results from the fourth National Drug Resistance SurveyImplementation of latent tuberculosis screening in HIV care centres: evaluation in a low tuberculosis incidence setting.Response to comment on "Community-wide isoniazid preventive therapy drives drug-resistant tuberculosis: a model-based analysis".Occupational lung disease in the South African mining industry: research and policy implementation.Tuberculosis screening and isoniazid preventive therapy implementation: a Brazilian experience.Modeling the implementation of population-level isoniazid preventive therapy for tuberculosis control in a high HIV-prevalence setting
P2860
Q27309915-4DD7CA93-577E-4794-B6BE-C1F2B2F6368AQ30240445-F9A444BC-8C22-4159-800B-1A71AB613B8AQ33820505-F5CFE144-CADF-4D9C-96C0-C6468A4B0835Q34011244-C959187D-B06F-40D0-B6D9-F8D0198C0194Q34146085-F514B913-27EE-456C-A626-898A180C731AQ34257658-245C8124-25F0-4CEE-99A5-D4ED7BD21691Q34515554-A5DE22E4-516E-41A3-9A4A-1AE0B130BD9EQ35336540-EE812C5D-740C-4EED-AA54-1611DB470AA1Q35567798-79007C4B-B1C4-4A7E-8532-9B0ABC9EA4F7Q35988353-41662420-EE58-4C91-A2C1-F4127AA2EC04Q36137225-9656574F-30B2-421B-95A8-B22DE6D36104Q36159344-78AF1552-8E06-486E-87C9-4BF588D9DAB2Q36702386-53220840-E6EB-4A81-AF1F-3A1601395FB5Q37021617-AE7C9942-D47F-42C3-8396-02B8B8F580DBQ37424113-B5E3DB7B-6BCE-4F5A-9AD6-9D90AB63B03AQ37664997-E0A137CB-9496-4BC4-A68F-769BDE58A32AQ37895251-BEC41413-385B-4EB5-A567-AD990ADB49BAQ38890668-B01710C5-60A7-4833-83CC-6E5DF01E5DDFQ40350029-1FA69233-5064-41F1-BC2E-21971580586EQ40625474-D94A8307-B091-4DBB-8AA9-CF36361B0B90Q40794905-C971BAB9-0CD0-43AE-A9EE-D03A0D53F57FQ41089864-049E9061-C71D-4075-86FD-01141ED49698Q43706761-9B83ACF9-EFF6-435D-8BC1-5815B56116EDQ46532712-824E3E39-A5EF-4EE3-948C-46D52A4E72F4Q51120505-CFDDC562-0C2B-437C-A119-D47300D0059DQ58718315-605E5E2E-A2BC-4ABD-9F01-9A62C028C78A
P2860
Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Tuberculosis outcomes and drug ...... a high HIV prevalence setting.
@en
Tuberculosis outcomes and drug ...... a high HIV prevalence setting.
@nl
type
label
Tuberculosis outcomes and drug ...... a high HIV prevalence setting.
@en
Tuberculosis outcomes and drug ...... a high HIV prevalence setting.
@nl
prefLabel
Tuberculosis outcomes and drug ...... a high HIV prevalence setting.
@en
Tuberculosis outcomes and drug ...... a high HIV prevalence setting.
@nl
P2093
P50
P1433
P1476
Tuberculosis outcomes and drug ...... a high HIV prevalence setting.
@en
P2093
Alison D Grant
Clare L van Halsema
Elizabeth C Russell
James J C Lewis
P304
P356
10.1097/QAD.0B013E32833849DF
P407
P577
2010-04-01T00:00:00Z